Curated News
By: NewsRamp Editorial Staff
November 16, 2026

Helus Pharma Posts $171.1M Cash, Advances Phase 3 MDD Program

TLDR

  • Helus Pharma holds $171.1 million in cash and has completed Phase 3 enrollment for HLP003, positioning it ahead in the depression treatment race.
  • Helus Pharma's HLP003 works as a novel serotonergic agonist to activate serotonin pathways and promote neuroplasticity in major depressive disorder.
  • Helus Pharma's NSAs aim to provide durable mental health improvements for people suffering from depression and anxiety, addressing a large unmet need.
  • Helus Pharma plans a Phase 2 study of HLP004 for generalized anxiety disorder in early 2027 and will select a candidate for HLP005 later that year.

Impact - Why it Matters

The mental health treatment landscape remains ripe for innovation, with major depressive disorder and generalized anxiety disorder affecting millions worldwide and many patients failing to achieve adequate response to existing therapies. Helus Pharma's progress with HLP003—now fully enrolled in its pivotal Phase 3 trial and backed by FDA Breakthrough Therapy Designation—signals a potentially faster path to a new class of serotonergic agonists designed to promote neuroplasticity and deliver durable improvements. If successful, these novel compounds could offer a much-needed alternative for patients with treatment-resistant conditions. The company's strong cash position of $171.1 million provides runway to advance not only HLP003 but also HLP004 for anxiety and its earlier-stage HLP005 program, positioning Helus Pharma as a notable player in the evolving psychedelic-inspired biotech space. For investors and patients alike, the next 12 to 18 months will be critical as key data readouts and trial initiations unfold.

Summary

Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has reported financial results and business updates for its fiscal second quarter ended Sept. 30, 2026, spotlighting progress in its novel serotonergic agonist (NSA) pipeline. The clinical-stage pharmaceutical company, founded in 2019, ended the quarter with $171.1 million in cash but posted a net loss of $103.1 million, compared with $33.7 million in the prior-year period. Operating expenses excluding share-based compensation rose to $39.6 million from $28.5 million, driven primarily by advancement of its Phase 3 clinical program. Cash used in operating activities totaled $35.3 million, versus $34.5 million a year earlier.

During the quarter, Helus Pharma completed enrollment in APPROACH, its pivotal Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder (MDD), while enrollment continued in the EMBRACE and EXTEND studies. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company also outlined plans to initiate a Phase 2 monotherapy study of HLP004 for generalized anxiety disorder in the first quarter of 2027 and expects to select a development candidate for its HLP005 program in the second half of 2027. Helus Pharma aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions through its proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. For more details, visit https://ibn.fm/yu74F.

The announcement was disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For company updates, visit www.helus.com.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Posts $171.1M Cash, Advances Phase 3 MDD Program

Blockchain registration record for this content